HomeNewsBusinessDisinvestment has opened the door for Air India to improve products and services, says Star Alliance CEO Jeffrey Goh

Disinvestment has opened the door for Air India to improve products and services, says Star Alliance CEO Jeffrey Goh

In a conversation with Moneycontrol from the Star Alliance headquarters in Frankfurt, Jeffrey Goh said AI going to the Tatas “will remove AI from any form of government involvement. It will provide AI with more autonomy in terms of investments in products and services.”

October 22, 2021 / 14:10 IST
Story continues below Advertisement
Air India | Representative image
Air India | Representative image

Jeffrey Goh, CEO of Star Alliance, the world’s largest grouping of airlines in terms of passengers carried, says it is good that the Air India (AI) disinvestment is finally through to “provide certainty for AI and also for its partners and, obviously, importantly the partners within the Star Alliance.”

Established in 1997, the association currently offers more than 19,000 daily flights to over 1,300 airports in 195 countries. It includes 26 global carriers such as AI, Lufthansa, United Airlines and Singapore Airlines.

Story continues below Advertisement

In a conversation with Moneycontrol from the Star Alliance headquarters in Frankfurt, Goh added that AI going to the Tatas “will remove AI from any form of government involvement. It will provide AI with more autonomy in terms of investments in products and services.”

Tata Consultancy Services (TCS) accounts for the largest outgo globally for the group. “I hope this partnership that we have with TCS will also enable a swifter technology transformation and digital transformation at AI,” Goh said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show